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Factor VIII (FVIII) is a key protein of the coagulation cascade, where it acts as the cofactor of activated factor IX. Upon activation, FVIII dissociates from von Willebrand factor and binds to phospholipids at the surface of activated platelets to form the tenase complex, thus leading to the activation of factor X, to a burst of generation of thrombin and to the formation of fibrin that consolidates the platelet clot. 1 Blood was collected on ACD-C buffer (124 mM sodium citrate, 130 mM citric acid, 110 mM dextrose, pH 6.5) from 12-14-week old mice by intra-cardiac puncture. Animals were handled in agreement with local ethical authorities (ethical committee in animal experiment "Charles Darwin" Ce5/2010/045). Platelets were purified in the presence of inhibitors (0.3 U/ml apyrase and 100 nM prostaglandin E1) as described. 6 The purity of platelets was greater than 99% as assessed by the expression of CD41 and size estimate (side scatter) by flow cytometry (data not shown). Platelets were then stimulated by the thrombin receptor-activating peptide TRAP-4. 7 The state of activation of platelets was estimated by the surface expression of Taken together, our data indicate that the absence of pro-coagulant FVIII in un-manipulated adult animals is associated neither with alterations in the activation status of circulating platelets nor with their ability to be activated. In patients with severe HA, the most significant morbidity is the development of arthropathy in joints, that results from recurrent intraarticular hemorrhages. In our laboratory conditions, FVIII° mice do not bleed spontaneously and do not experience premature mortality. Indeed, FVIII° mice do not develop arthropathy unless bleeding is experimentally provoked in the articulations. 8, 9 Whether the state of activation and responsiveness of platelets differs under conditions of chronic hemorrhages in haemophilic mice remains to be investigated.
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